The whole biotech sector is in "sell the news" and "risk off" mode, with too much hot money chasing the sector over the past year. Now, the short sellers are capitalizing on the downtrend. What's new about that?
For some reason, an option player is still betting big bucks for the stock to be over $5 a share before long. Gevo is a solid drug with multiple indications, but nothing blockbuster at this stage. If EOA data look impressive at 6 months (leveling off of placebo and further positive trends for tx arm), alongside other indications which are forthcoming, we will see at least $8-10 in late 2014. I'm betting that Gevo pays the bills until X-Met lights the rocket. GLTA